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THE PHARMACEUTICAL INDUSTRY:
A Pharmacy Student’s Guide

Christian Egly, PharmD Candidate, and Yaman Kaakeh, PharmD,
BCPS, BCNSP, CNSC, BCCCP, College of Pharmacy
STUDENT AUTHOR BIO SKETCH
Christian Egly is a fourth-year (P4) pharmacy student in the Purdue University College of Pharmacy. During his years
at Purdue, he worked in labs performing bench research in clinical pharmacology and biochemistry. He plans to work in
the pharmaceutical industry after graduation. During his fourth year, he completed rotations in business development at
Kashiv Pharma, LLC, and was hired there for an internship in 2017. In the article, Christian describes his personal experiences at Kashiv Pharma, LLC, and how industry can positively affect patient communities.
INTRODUCTION AND BACKGROUND
WITH LITERATURE REVIEW
Pharmaceutical industry positions and job descriptions
are largely unknown to pharmacy students. A recent
article showed that pharmacy students are aware of
postgraduate training programs, such as fellowships;
however, evidence shows students do not receive enough
information about industry career opportunities while
in pharmacy school (Audette, McGann, Horton, &
Silva, 2014; Shpilfogel, Tyrrell, & Alexander, 2015a;
Yung, Johal, & Pan, 2004). Despite a lack of knowledge
about career opportunities, the number of fellowship
positions filled each year has grown significantly. The
current number of fellowships occupied by pharmacists
is approaching 450—an increase from 250 positions four
years prior (Alexander, Dipsia, Wells, & Singh, 2018).
Departments included under fellowships are medical
affairs, regulatory affairs, clinical research and development, commercial, health outcomes research, and more.
The primary purpose of this article is to describe how
a career in industry is beneficial to a variety of constituents, including patients, health care providers, and
students. A secondary purpose is to highlight ten primary industry positions for pharmacists. By detailing a
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personal experience in industry, other pharmacy students
can have a better glimpse of a unique career path and
what this type of work involves.
METHODOLOGY
The Industry Pharmacist Organization (IPhO), the
Rutgers Fellowship Brochure (Rutgers, 2017), and other
sources were utilized to summarize ten pharmaceutical
industry positions for pharmacists. Details of the different areas can be found in Table 1. In addition, depending
on the company, some jobs may integrate multiple
departments; for example, medical information and
medical affairs positions have multiple similarities.
Departments with the most fellowship positions filled by
pharmacists as of 2018 are medical affairs followed by
regulatory affairs (Alexander et al., 2018). Opportunities,
besides those mentioned, within early clinical development
include clinical pharmacology and translational medicine.
Students with an interest in pharmacokinetics/pharmacodynamics (PK/PD) should look into clinical pharmacology
(Goh, Alrawi, & Lozito, 2006). Translational medicine
would involve bench to bedside research integrating both
basic science and clinical research aspects. Firsthand experience seems to be the ideal way for pharmacy students to
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understand industry positions. My own personal experience
at Kashiv Pharma, LLC can be seen in the next section.
STUDENT EXPERIENCE
Kashiv Pharma is located in Bridgewater, New Jersey.
The company specializes in 505(b)2 products, which
is an accelerated approval pathway for reformulations
of current drugs. For instance, a product approved, but
dosed four times a day, has the potential to be reformulated. Reformulating the product could allow for
once-daily dosing and would benefit patients in terms
of compliance, better pharmacokinetics, level of effectiveness, or improved safety profile. I will explain my
experience from working in the market research or business development sector as a rotation student and intern.
Daily responsibilities included reading clinical trials,
utilizing Intercontinental Marketing Services (IMS) data
for prescription volume and sales, scanning patents,
searching for other drugs in development using a program called PharmaCircle™, and utilizing various other
sources. After compiling the information, I would make
a document summarizing the data in order to explain the
information to other people in the company. Final steps
would be to determine whether the product concept was
worth pursuing or if it should be abandoned.
Here is an example of how a typical product would be
evaluated. Let’s call the drug Product X. Product X
is currently dosed three to four times per day and has
adverse side effects. Using IMS data, the product had 12
million prescriptions written last year and $360 million

in sales, which tells us there is a good market for the
drug. Next, looking at clinical trial information and the
package insert can give us detailed clinical information
about the product. Questions to answer include:
1. What does the PK/PD profile look like?
2. How effective is the medication?
3. Has there been an extended release product in
clinical development before?
4. What does the safety profile look like?
5. Are side effects related to peak/trough
concentrations of the drug?
Answering these questions starts to delineate the product
concept, which would give an impression whether Product X is capable of being improved or not.
Some surprising facts can come from a literature review.
For instance, a few articles showed that extended release
products previously existed for certain medications we
were evaluating. The extended release product was even
superior to the immediate release, but for unknown reasons, it was discontinued during development or in the
post-market phase. If discontinuation occurs, it is important to determine the root cause. Was the profit from the
drug not enough to sustain development? Did a company
acquire a more important project? These are important
questions to ask.
Once clinical trials, IMS data, and package insert data
have been scoured, the competitive atmosphere must be

Figure 1. A snapshot of typical Pharmacircle information for the drug clopidogrel. The site gives
different phases of drug development and other information.
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Table 1. Results: Industry positions and responsibilities for pharmacists.

Position Title

Main Roles

Early Phase Clinical
Development

Phase I–Phase IIa
clinical trials

Late Phase Clinical
Development

Phase IIb–Phase IV
clinical trials

Commercial
Functions/Marketing

Sales and product
advertising material
production

Medical
Communications,
Education, and
Information

Education and
information related to
product

Regulatory Affairs

Communications
with FDA and other
regulatory agencies

Medical Science
Liaison (MSL)

Fieldwork; education
to medical experts
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Detailed Responsibilities
1. Manage trials
2. Evaluate study protocols
3. Summarize trial findings in reports
4. Select and collaborate with trial site, Contract Research
Organizations (CROs)
5. Safety, tolerability, Pharmacokinetics/Pharmacodynamics (PK/
PD), drug-drug and drug-food interactions, dosing, and pilot
efficacy
1. Manage trials
2. Evaluate study protocols
3. Select and collaborate with trial site, Contract Research
Organizations (CROs)
4. Summarize trial findings in reports
5. Efficacy studies with larger populations
6. Long-term effects
1. Oversee marketing materials by participating in medical and legal
peer review committee
2. Manage expenditures of marketing and determine return on
investment (ROI)
3. Collaborate with market research/business analytics department
4. Work with sales training force
1. Respond to information requests about a product from patients,
families, physicians, etc.
2. Formulate database with responses to medical inquiries
3. Review promotional materials
4. Plan educational materials through collaboration with Key Opinion
Leaders (KOLs), managed care and academia
1. Regulatory communications throughout development of a product
(discovery to post-marketing studies)
2. Document production and analysis
• Investigational New Drug (IND)
• New Drug Application (NDA)
3. Review/revise product labeling
4. Review/revise advertising and promotional materials to ensure
complies with regulations
5. Consult with preclinical and clinical studies to ensure data
required by regulatory agencies is generated
1. Maintain relationships with medical experts in specific therapeutic
area within a geographic area
• Education for clinicians and sales force
• Communicate with internal stakeholders
• Relationships with managed market teams
2. Involves 60–80% travel time
• Travel to hospitals or CRO sites for clinical trials (training
and communication)
3. Ensures compliance for credentialing of trial sites (background
checks, medical testing (i.e., Tuberculosis test) and immunization
verification, training on facility policies, HIPPA agreements, etc.)
4. Development of educational materials
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Table 1. (Continued)

Medical and
Scientific Affairs

Medical education
materials and
communications with
customers

Drug Safety and
Risk Management
(Pharmacovigilance)

Drug safety
evaluations and
informational updates

Health Economics
and Outcomes
Research (HEOR)

Costs and
consequences of
products

Business
Development and
Market Research

Assess unmet
needs in medical
community and
financial incentives
of developing certain
products

1. Establishing relationships with medical directors, MSLs, KOLs,
and health outcomes/economics researchers
2. Provide transparency for ongoing trials, milestones, and other
pertinent information through annual reports and news blurbs to:
• Internal and external stakeholders
• Customers
• Prescribers
3. Bridge between research and discovery to commercialization
4. Present educational materials about products or therapeutic
landscape
5. Provide support for clinical studies in off-label indications
1. Monitor, assess, and evaluate safety profile of product throughout
lifecycle
2. Submit documents summarizing safety profile and concerns,
including:
• Annual reports
• Investigational brochures
• Risk assessments
• Risk management plans (RMPs)
• Risk Evaluation Mitigation Safety (REMS)
3. Anticipate regulatory problems with safety assessments and
develop ways to deal with the concerns
4. Participate in clinical development with focus on safety
1. Provide proof of product’s market value for medical intervention
(device or medication), which can be used for:
• Market access
• Pricing
• Formulary decisions
• National/international clinical guidelines
2. Support market and sales teams by utilizing publications, Quality
of Life (QOL), Quality Adjusted Life Years (QALYs), health care
models, etc.
3. Publish and present health outcomes research
4. Develop patient reported outcomes assessments
1. Evaluate market trends, utilize internal and external relationships,
and analyze clinical data to identify opportunities to add to company’s
portfolio
2. Determine whether to keep certain activities within the company or
outsource to contract organizations
3. Collaborate with medical affairs, intellectual property (legal),
regulatory affairs, marketing, HEOR, and managed markets
4. Ensure internal stakeholders’ views align with external stakeholders
to uphold appropriate return on investment and mutual benefits

evaluated. What other products for the disease state are
already on the market or in clinical development? Pharmacircle™ is a database that can show the current stage of
development for a medication, which is particularly useful
for evaluation of competitors. For example, Pharmacircle™ shows whether a product is in preclinical, clinical
trial phases (I–IV), on the market, or has been discontinued. The software also includes links to the websites of

the companies that manufacture the drug. Important information from company websites includes news articles or
annual reports highlighting the progress of the medication.
In some instances, PharmaCircle™ may show that a drug
is still in clinical development. However, the company
website may have a recent press release showing negative
results of the most recent trial. The assumption is that the
drug would likely be discontinued.
research with reflection 75
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Patents help to understand if a certain technology or
formulation has already been assessed. For instance, one
of the products Kashiv evaluated was initially unstable.
An outside researcher came to Kashiv for a partnership, claiming he had invented a technology that gave a
stable formulation. He also claimed the formulation was
completely novel. After searching patents, it was discovered that two to three other formulations existed and had
patents for the same product. Not only were there patents
for stable formulations of the drug, but a similar product was already marketed in Germany. The person who
came to the company asking for a partnership did not
have their own patent at the time.
After data has been gathered from IMS, clinical trials,
package inserts, PharmaCircle™, and elsewhere, the
next steps could be taken, which involve external assessments of the product concept. These include talking
with key opinion leaders (KOLs), submitting surveys
to clinicians that use the current medication in practice,
and contracting with other market research firms for
discussions with pharmacy benefit managers (PBMs).
Discussions with PBMs evaluate the likelihood that the
new formulation of Product X will be covered by insurance. Talks with KOL’s usually involve a phone call to
experts in the field. Generally, these are medical doctors
who extensively prescribe the medication and may have
been involved in published articles covering the drug
in question. The phone call is important to understand,
from a primary source, how often the medication is used
and how the drug compares to other medications for the
same indication. Most often, the information the medical doctor gives coincides with the original research;
however, if their opinion differs significantly, further
evaluation of the literature is necessary. Feedback from
multiple physicians is important. Interviewing multiple
KOL’s will generally give a good trend and help to see if
there are outliers.

Figure 2. U.S. patent search results for amiodarone
compositions. Notice not all results are directly related, but may
only mention amiodarone formulations.
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Table 2. Review of various tiers according to payer system,
most ideal tier for approval would be tier 3. Preferred brands
are mostly covered by insurance and take initial precedence in
prescription utilization over tiers 4 and 5.

1
2

Prefered Generics
Generics

Cost (1, lowest–
5, highest)
Minimal (1)
Low (2)

3
4
5

Prefered Brands
Non-preferred
Specialty

Medium (3)
High (4)
Max (5)

Tier

Drug Type

Market research surveys are sent to physicians. Kashiv
uses a contract organization to deliver the surveys to
multiple physicians (example n = 25). These surveys
generally use Likert scales (ratings of 1–10) to gather
information. Criteria assessed for the medication generally include clinical effectiveness, side effects, and how
the medication compares to others that treat the same
disease state. Eventually, the product concept (Product
X) is discussed with the physicians taking the survey.
Finally, the physicians evaluate the need for improvement to the current formulation, how they believe
reformulating will effect safety and efficacy, whether
they think they would prescribe more of the drug after
the reformulation, and so forth. Comparing survey data
with data from existing clinical trials is important to
ensure that the data matches. An example of conflicting
evidence includes adverse event reporting in clinical trials differing from the amount of adverse events reported
by physicians in the surveys or phone calls.
Another aspect of market research involves discussing the
product concept with pharmacy benefit managers (PBMs).
If Product X will not be covered by insurance, the likelihood of the product failing on the market increases. The
same company that performs physician surveys is contracted by Kashiv for market research with PBMs. The
contract company will usually make phone calls or visits
with PBMs to discuss the current product, other medications on the market, and the concept of Product X. The
PBM will provide information on which tier the current
drug is covered, a forecast for the tier that developed
Product X will be placed into, and their estimation for the
cost of the product. The data gathered is generally a rough
estimate, but it’s important to determine w insurance companies will likely think about Product X when the drug is
marketed. From personal observation, it seems difficult to
get PBMs to see the benefit of once-a-day prescriptions
without further evidence. For this reason, clinical trials of
505(b)2 products should aim to prove that Product X will
be once a day and that it will improve the effectiveness
and/or safety over the current formulation.
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Generally, the steps above are the majority of the work
done in business development. Next steps include meeting with members of the company to discuss market
research data and to determine if Product X is a candidate for further development. If Product X is a good
candidate, it will move on to the formulations team.
Once a formulation is developed, the medication moves
into clinical trials and to market, assuming success at
each stage. Since the medication that Product X is based
on is already on the market, the development process
is generally much shorter than it is for a new chemical
entity (NCE). The pathway for improved formulations is
called the 505(b)2 pathway by the FDA. For NCEs the
pathway follows a 505(b)1 route.
COMMUNITY IMPACT
Industry pharmacists’ impact on pharmaceutical development could be largely beneficial to patients in the
future. Products that pharmacists in industry develop
could reduce pill burden, increase compliance, increase
effectiveness, and reduce adverse effects associated with
current therapies. By focusing on 505(b)2 products,
the timeframe to bring these medications to market is
greatly reduced compared to development of an NCE,
allowing patients to access the medications sooner.
Products evaluated at Kashiv Pharma cover patients in
all age ranges so there is a large population that may be
positively affected. Working with PBMs can allow for
reduced prices of the medications to patients as well.
Improvement to medications not only impacts patients,
but also the work of health care providers. Work in
industry can profoundly impact health care systems,
such as hospitals, long-term care facilities, and so forth.
For instance, new medications could affect treatment
guidelines for various disease states.

Other people potentially impacted by this article are
pharmacy students. By sharing personal rotation and
internship experiences, pharmacy students may benefit
by having a glimpse into pharmaceutical industry work
before having firsthand experiences.
STUDENT IMPACT
This article may give pharmacy students an opportunity
to pursue further knowledge and understanding about the
pharmaceutical industry. There is likely a lack of knowledge about what industry positions can be filled and the
general work requirements of each. A better understanding exposes students to rewarding career options. Below
are other pathways students can pursue to learn more
about the pharmaceutical industry.
A couple of organizations specific to career paths in
industry are the Industry Pharmacists Organization
(IPhO) and the International Society for Pharmaceutical Engineering (ISPE). IPhO is specific to positions
in industry that pharmacists usually take, which were
summarized in the table earlier. The IPhO website
provides information about professional development,
fellowships, and careers, as well as published articles
highlighting aspects of the pharmaceutical industry.
Advanced pharmacy practice experiences (APPEs) are
another great way to obtain experience in the pharmaceutical industry. Many pharmacy students in my class
have enjoyed rotations at Eli Lilly. Purdue University
also provides track rotation opportunities, which can be
two- to three-month experiences at one pharmaceutical
company. A rotation at the Food and Drug Administration (FDA) in Washington, DC, is another experience
that would be valuable to students considering industry.
The department of regulatory affairs is currently the
second-largest fellowship by the number of pharmacists,
which requires extensive FDA communication. Having firsthand experience with the FDA might be viewed
highly by companies when applying to Regulatory
Affairs or other industry positions.
Internships are another pathway to obtain industry
experience. My internship at Kashiv lasted two months,
and I gained a considerable amount of knowledge during that time. An internship provides early experience
in positions that can be acquired after pharmacy school.
Networking is key in industry, and having an internship
starts to develop a student’s network.

Figure 4. 505(b)1 traditional NCE pathway vs 505(b)2
reformulation pathway. (Courtesy of Stegemann et al.)

Fellowships can also significantly help with networking. The Rutgers pharmaceutical industry fellowship
community partner snapshots 77
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Figure 5. Note the difference in time for production between each pathway. (Courtesy of Camargo Pharmaceutical Services.)

has approximately 200 current fellows. Each fellow has
an opportunity to meet others through weekly activities
at Rutgers College of Pharmacy and other partnerships.
Pharmacists can pursue a wide variety of positions, as highlighted by the information earlier. However, a fellowship is
not a requirement to break into the pharmaceutical industry.
In fact, only 20% of current industrial pharmacists completed a fellowship (Alexander et al., 2018). Many started
out as clinicians and transferred to industry or went straight
into industry from pharmacy school. Oftentimes fellowships can provide an accelerated track to director roles.
Guest speakers and pharmacy school curriculum provide
another avenue to learn about the pharmaceutical industry.
Industry professionals occasionally come to speak about
their work. One article evaluating 193 pharmacy students
showed that 30% of students first learned about careers in
the pharmaceutical industry from a guest speaker (Shpilfogel, Tyrrell, & Alexander, 2015a). Other times, pharmacy
schools will have electives that students can take to learn
more about industry. One ten-week course at the Massachusetts College of Pharmacy and Health Sciences (MCPHS)
covering industry showed a significant improvement in
first-year pharmacy (P1) students’ knowledge across seven
functional industry careers. The course improved student
industry interest, from only 55% saying they were interested to 70% being interested in an industry career, and
from 45% to 75% saying they had a specific area of interest
by the end of the class (Audette et al., 2014).
CONCLUSION
Pharmacists are sought out for their broad clinical and
scientific knowledge by pharmaceutical companies. This
article touches on many of the different positions available to pharmacists through fellowships. There are several
other industry positions besides those mentioned, such as
manufacturing. Direct pharmaceutical experience through
rotations, internships, or fellowships are important not only
for training experiences, but also for building a professional
network. In addition, joining pharmaceutical organizations such as IPhO and/or ISPE to meet peers interested in
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industry helps, as involvement provides multiple networking opportunities. I suggest taking pharmaceutical industry
courses to understand more about the career opportunities.
I hope my experiences provide a glimpse of responsibilities
that a pharmacist may have in industry.
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